Gaming studio Supercell to expand on Tencent's WeChat with installation-free mini games
Finnish video game studio Supercell, developer of Clash Royale and Brawl Stars, is set to launch its popular titles on
Tencent Holdings
WeChat as installation-free mini games, leveraging the super app's vast user base.
Advertisement
Jakub Barczyk, business and operations lead for Supercell's Clash of Clans, said on Wednesday that Brawl Stars was already available on WeChat, known as Weixin in mainland China, while Clash Royale was 'currently being developed' for a September release on the WeChat mini-game platform. He made the remarks during a live-streamed session at a WeChat event in Chongqing.
Helsinki-based Supercell 'is focusing on seamless integration between the platform and mobile games, enabling effortless switching through synchronised assets', Barczyk said. 'This approach accommodates both existing players, ensuring their progress is saved, and new players, who will benefit from a streamlined experience.'
'This strategy aims to seamlessly integrate Supercell's popular games into the everyday routines of Chinese users through WeChat, providing easy access with classic experiences,' he added.
Barczyk said Supercell was focusing on WeChat mini games because of the rapid growth of the market and the rising popularity of lightweight games that can be played almost instantly without downloading a separate app.
Advertisement
Since WeChat launched mini games in 2018, which run entirely within the super app, they have amassed 500 million monthly active users. Over 300 mini games had achieved quarterly sales of more than 10 million yuan (US$1.4 million), according to WeChat data released on Wednesday.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
South China Morning Post
40 minutes ago
- South China Morning Post
Keung To's fall into sea: was it a cry for help for Hong Kong band Mirror?
Hong Kong Cantopop boy band Mirror is navigating a challenging landscape after its meteoric rise to fame a few years ago, with its members now forced to compete with all types of online entertainment and the local showbiz scene grappling with broader headwinds, market observers have said. Advertisement They also said that, despite immense public expectations, the band's human vulnerabilities, paired with a local industry that distinctively lacks the rigorous pre-debut training like that of K-pop idols, created unique challenges. They needed support to grow and expand beyond their initial amateur appeal and that might have been lacking, industry observers said. Formed through ViuTV's reality talent show in 2018 and swiftly hailed as Cantopop's saviours, Mirror quickly amassed a massive fan base along with loyal brand partnerships and advertisers. But the band now faces renewed public scrutiny after popular member Keung To was rescued following his fall into the sea on Tuesday. Advertisement The 26-year-old singer later revealed he had consumed alcohol and painkillers before the accident. Keung, along with other members such as Anson Lo Hon-ting, Edan Lui Cheuk-on and Ian Chan Cheuk-yin, blossomed into multitalented stars, excelling with their solo music careers, acting roles and variety shows, further cementing the band's collective and individual appeal.
The Standard
an hour ago
- The Standard
Cyberport landmark to help reshape HK tech ecosystem
Artist impressions of Cyberport 5, whose advanced smart office facilities are expected to help boost research and development in AI and other fields.
South China Morning Post
4 hours ago
- South China Morning Post
China's drug innovators tap AI to quicken discovery, slash costs, win deals
A deal between Shenzhen-based XTalPi and US firm DoveTree shows Chinese biotech AI capabilities are gaining recognition Upstart Chinese drug innovators are joining their foreign competitors in deploying more artificial intelligence (AI) tools to reduce the costs of discoveries in an effort to shorten the route to clinical trials and commercialisation. Genscript Biotech, based in Nanjing in eastern Jiangsu province, is developing in-house AI tools - using its enzyme prediction database and an algorithm for altering the DNA sequence of a gene - to identify and optimise promising candidates based on protein sequences and therapeutic targets, according to analysts at Jefferies. XTalPi, a Shenzhen-based AI-powered new drugs research firm, announced on Monday a deal with US firm DoveTree for global commercialisation rights to its drug candidates for multiple oncology, autoimmune and neurological diseases. Boston-based Insilico Medicine published the results of its phase two trial of rentosertib in the Nature Medicine journal, claiming the first proof-of-concept clinical validation of AI-driven discovery. Its drug candidate was tested for idiopathic pulmonary fibrosis, a chronic and progressive disease characterised by the scarring of lung tissue. A laboratory owned by QuantumPharm, also known as XtalPi, in Shenzhen. Photo: Handout At stake is a business that is projected to grow exponentially in the next decade. The market for AI-assisted drug discovery could reach US$13 billion by 2032 from US$1.5 billion in 2023, Coherent Solutions said in a report in April. Spending on AI-based clinical research tools could exceed US$7 billion by 2030, the software engineering firm said. AI enabled the processing of vast data, such as the genetic and protein content of biological samples, and clinical trials data more accurately and faster, according to Nebius, a Netherlands-based AI infrastructure and software provider. 'Drug innovation was slow, expensive and often bogged down by clunky infrastructure,' said Ilya Burkov, its global head of healthcare and life science. 'AI platforms can help identify novel targets and design promising new drug candidates in as quick as 18 months, compared to five to seven years, traditionally.' Newsletter Every Saturday SCMP Global Impact By submitting, you consent to receiving marketing emails from SCMP. If you don't want these, tick here {{message}} Thanks for signing up for our newsletter! Please check your email to confirm your subscription. Follow us on Facebook to get our latest news. While AI-assisted efforts are relatively new and none of the candidates have reached commercial status, the potential lies in the predictive power of AI models in accurately translating animal test results into clinical applications on human bodies, according to Goldman Sachs. China's new cancer drug gets US approval at huge price mark-up 'This is where the biggest bottleneck is and where the real disruption can happen,' said Chen Ziyi, head of Asia healthcare research at Goldman, in an interview. 'AI is promising with lots of hopes and unknowns, hopefully it will get smart enough for us to get there.' AI-assisted efforts have gained momentum in China's healthcare industry over the past five years, aided by technical advancement, policy incentives and capital investment, Jefferies said. The XTalPi deal showed Chinese biotech AI capabilities have also been recognised globally. DoveTree, which has three drugs approved by the US Food and Drug Administration, will pay XTalPi US$100 million within 180 days of a definitive agreement for the commercialisation rights to candidates for multiple oncology, autoimmune and neurological disease targets. Other global firms are also making headway, according to Goldman's Chen. One example is AlphaFold, a predictive AI tool developed by London-based Google DeepMind. By predicting protein structures with high accuracy, it enhances researchers' capability to identify potential drug targets and design drugs that attach them more effectively. Other technologies in the works include the use of artificial organs for virtual preclinical modelling to replace animal testing, he said. One example is the use of microchips lined with living human cells to mimic the structure and function of human organs to enable researchers to study how they respond to drug candidates.
